Ontario Genomics funded a project to help understand the complex origins of Canada, and the relatedness (or lack thereof in this case) between Maritime Archaic people and the Beothuk. The technology being developed by Hendrik Poinar’s group at McMaster University has kept them at the forefront of paleo-DNA technology. Poinar has leveraged this funding to secure funding from other sources, including Illumina. The surprising results of this study were published in Current Biology (Duggan et al., 2017, Current Biology 27, 1–8) and appeared in a recent Globe and Mail article
The Chair of the Ontario Genomics Board of Directors, Brian Underdown, is pleased to announce the appointment of Dr. Deb Stark, Dr. Benjamin Rovinski and Dr. Alan Winter to its Board. Dr. Stark is the former Deputy Minister of the Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) and brings a wealth of experience…
The Smithsonian Institution’s first state-of-the-art exhibition about genomic science, Genome: Unlocking Life’s Code, opens October 7, for the first time in Canada at Science North in Sudbury, Ontario. The exhibition examines the complexities of the genome — the complete set of genetic or hereditary material of a living organism — and chronicles the remarkable breakthroughs that have taken place since the completion of the Human Genome Project more than a decade ago. It will be at Science North until January 7, 2018.
Alnylam Pharmaceuticals Inc. unveiled positive results from a late-stage clinical trial of the drug patisiran for the treatment of familial amyloidotic polyneuropathy. Patisiran works by interrupting the production of a specific disease-causing protein through a process called RNA interference (RNAi), which eliminates unwanted proteins. Because RNAi can be easily tuned (in theory) to any disease, this may herald a new class of medicines.
The founding principle of Toronto-based Deep Genomics is “that the future of medicine will rely on artificial intelligence (AI), because biology is too complex for humans to understand.” After success at the startup assistance program run by University of Toronto’s Creative Destruction Lab, Deep Genomics has now closed a Series A financing deal that will allow it apply AI to search across 69 billion molecules to identify 1000 potential drugs.
On September 25th, 2017, Ontario Genomics, in partnership with the Synthesis Agri-Food Network and supported by Genome Canada and the Natural Sciences and Engineering Research Council, held a workshop to discuss “The Genomics Strategy for the Ontario Agriculture and Agri-Food Sector”. Over 80 leaders from across Ontario’s diverse and strong agriculture and agri-food sector attended…
The past week saw the appointments of leaders in key positions across Canada’s and Ontario’s research and innovation ecosystem, including Canada’s Chief Science Advisor, CEO of MaRS Discovery District, and CEO of the newly created Vector Institute for Artificial Intelligence. Dr. Bettina Hamelin, President and CEO of Ontario Genomics, would like to congratulate Dr. Mona…
J. Craig Venter and Human Longevity published a paper making the bold claim that it can identify individuals using their genomes to predict what their faces looks like. But criticism over social media and BioRxiv has called this into question, or at least stated this technology needs more development before being robust enough to predict faces from genomes.
Understanding a cancer’s genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research (OICR) announced the “OCTANE” study that will use next-generation genome sequencing to select the best treatment option for participants.
Doctors at Sick Kids have developed tests to analyze the molecular makeup of individual brain tumours, leading to the possibility of personalized treatment. Hospitals from around the world are sending their patient’s tumour samples to Sick Kids for this molecular analysis.